Stocks and Investing Stocks and Investing
Thu, July 13, 2023

Matthew Sykes Maintained (TXG) at Strong Sell with Increased Target to $30 on, Jul 13th, 2023


Published on 2024-10-28 04:47:43 - WOPRAI, Matthew Sykes
  Print publication without navigation


Matthew Sykes of Goldman Sachs, Maintained "10x Genomics, Inc." (TXG) at Strong Sell with Increased Target from $25 to $30 on, Jul 13th, 2023.

Matthew has made no other calls on TXG in the last 4 months.



There are 5 other peers that have a rating on TXG. Out of the 5 peers that are also analyzing TXG, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Matthew


  • Mason Carrico of "Stephens & Co." Reiterated at Buy and Held Target at $65 on, Thursday, May 18th, 2023
  • Luke Sergott of "Barclays" Initiated at Buy and Held Target at $65 on, Wednesday, May 10th, 2023
  • Dan Brennan of "TD Cowen" Maintained at Buy with Increased Target to $66 on, Thursday, May 4th, 2023
  • Daniel Arias of "Stifel" Maintained at Strong Buy with Increased Target to $68 on, Thursday, May 4th, 2023
  • Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $65 on, Thursday, May 4th, 2023
Contributing Sources